Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.

Shee, Kevin; de la Calle, Claire M; Chang, Albert J; Wong, Anthony C; Feng, Felix Y; Gottschalk, Alexander R; Carroll, Peter R; Nguyen, Hao G

Shee, Kevin; de la Calle, Claire M; Chang, Albert J; Wong, Anthony C; Feng, Felix Y; Gottschalk, Alexander R; Carroll, Peter R; Nguyen, Hao G.

Afiliação

Shee K; Department of Urology, University of California, San Francisco, California.
de la Calle CM; Department of Urology, University of California, San Francisco, California.
Chang AJ; Department of Radiation Oncology, University of California, Los Angeles, California.
Wong AC; Department of Radiation Oncology, University of California, San Francisco, California.
Feng FY; Department of Urology, University of California, San Francisco, California.
Gottschalk AR; Department of Radiation Oncology, University of California, San Francisco, California.
Carroll PR; Department of Radiation Oncology, University of California, San Francisco, California.
Nguyen HG; Department of Urology, University of California, San Francisco, California.

Adv Radiat Oncol ; 7(5): 100941, 2022.

Article em En | MEDLINE | ID: mdl-35847550

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google